九品芝麻官

8月14日人民币对美元中间价报6.7878，调升10个基点_我的网站

A |     　　讯 8月14日，人民币对美元中间价报6.7878，调升10个基点，前一交易日中间价报6.7888。　　中国人民银行授权中国外汇交易中心公布，2026年8月14日银行间外汇市场人民币汇率中间价为1美元对人民币6.7878元，1欧元对人民币7.8017元，100日元对人民币4.2454元，1港元对人民币0.86500元，1英镑对人民币9.1262元，1澳大利亚元对人民币4.7770元，1新西兰元对人民币3.9587元，1新加坡元对人民币5.2850元，1瑞士法郎对人民币8.3136元，1加拿大元对人民币4.8539元，人民币1元对1.1914澳门元，人民币1元对0.60339林吉特，人民币1元对12.3156俄罗斯卢布，人民币1元对2.3917南非兰特，人民币1元对209.93韩元，人民币1元对0.54326阿联酋迪拉姆，人民币1元对0.55529沙特里亚尔，人民币1元对46.5198匈牙利福林，人民币1元对0.55184波兰兹罗提，人民币1元对0.9583丹麦克朗，人民币1元对1.4142瑞典克朗，人民币1元对1.4065挪威克朗，人民币1元对7.07462土耳其里拉，人民币1元对2.5137墨西哥比索，人民币1元对4.9134泰铢。    

    Medicine File photo: VCG
China has granted marketing approval of its first drug for the prevention of acute mountain sickness, filling the long-standing gap in the domestic market where no such medications had been available, Science and Technology Daily reported on Tuesday.
The National Medical Products Administration (NMPA) has approved the marketing of acetazolamide sustained-release capsules, the report said. As the first specialized drug in China indicated for preventing of acute mountain sickness, its approval marks the end of the country's lack of dedicated preventive treatment for altitude illness. 
By inhibiting the activity of carbonic anhydrase, acetazolamide promotes the renal excretion of bicarbonate, corrects respiratory alkalosis caused by hypoxia at high altitudes, thereby regulating acid-base balance, optimizing respiratory status, elevating blood oxygen levels, and reducing the risk of onset at the source. 
In contrast to health products that only provide auxiliary regulatory effects, this medication has been validated through stringent clinical trials and stands as a specialized drug approved by the NMPA with a clear indication for prevention, said the report.
Led by principal investigator is Luobu Gesang, a deputy dean of the People's Hospital of Xizang Autonomous Region, the clinical trial was designed by his team and has yielded critical evidence to inform prevention strategies for altitude sickness that are specifically adapted to Chinese and Asian populations. 
"Previously, although acetazolamide had already been used internationally for the prevention of acute mountain sickness, China had long lacked an NMPA-approved acetazolamide formulation supported by rigorous clinical trials. Furthermore, the existing international formulations were short-acting tablets requiring multiple daily doses, and no drugs with the relevant indication were available on the domestic market for an extended period," said Luobu Gesang.
The sustained-release capsule approved this time not only fills this critical gap but also optimizes the dosage form, providing more reliable and convenient medication protection for the physical health and life safety of people entering high-altitude areas, he added.
Clinical trials showed that, compared with the placebo group, the incidence of acute mountain sickness in the medication group was significantly reduced, with the incidence of moderate-to-severe acute mountain sickness decreasing by 14.6 percent, according to the report.
Related research has been published in the international flagship journal of high-altitude medicine, High Altitude Medicine & Biology.
Global Times
。版权申明：凡注有“”或电头为“”的稿件，均为独家版权所有，未经许可不得转载或镜像；授权转载必须注明来源为“”，并保留“”的电头。

B |     。

Current article:http://7we2.yepenchunshouzuiwai.shop/list_24feb3/xxn3.html

Published on:00:00:00